Visterra Makes Debut at ICAAC with Flu Antibody, Partnership
By Anette Breindl
Tuesday, September 11, 2012
The typical way to identify a broadly neutralizing antibody is to screen B cells for one, and then look for an epitope that can induce its production. Cambridge, Mass.-based start-up Visterra Inc. used a very different approach to come up with its VIS410, an antibody that is capable of neutralizing all strains of influenza A that the company has tested.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.